S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung.
Hao M, Fu R, Tai J, Tian Z, Yuan X, Chen Y, Wang M, Jiang H, Ji M, Lai F, Xue N, Bai L, Zhu Y, Lv X, Chen X, Jin J.
Hao M, et al. Among authors: yuan x.
Acta Pharm Sin B. 2023 Mar;13(3):1110-1127. doi: 10.1016/j.apsb.2022.10.006. Epub 2022 Oct 12.
Acta Pharm Sin B. 2023.
PMID: 36970190
Free PMC article.